Sorrento Therapeutics Announces Entry Into Option Agreement to Exclusively License MPRO Inhibitors Against SARS-CoV-2 and Variants of Concern, Including Delta, From Texas A&M University
24 août 2021 10h44 HE
|
Sorrento Therapeutics, Inc.
MPro is a SARS-CoV-2 enzyme that catalyzes the formation of a number of essential proteins for the viral reproduction.MPro inhibitors block this catalytic process to potentially inhibit the viral...
Adamis Pharmaceuticals Announces a Publication with the Human Immune Monitoring Center at Stanford Demonstrating Tempol Significantly Inhibited Multiple Cytokines from COVID-19 Patient’s Cells
24 août 2021 07h30 HE
|
Adamis Pharmaceuticals Corporation
Tempol: A potential home treatment for COVID-19 (https://covid19.nih.gov/news-and-stories/tempol-potential-home-treatment-covid-19). Trial to begin shortly. SAN DIEGO, Aug. 24, 2021 (GLOBE...
Adamis Highlights National Institutes of Health (NIH) Article Entitled, “Tempol: A Potential Home Treatment for COVID-19”
19 août 2021 07h30 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today highlighted that the NIH has identified Tempol as a potential home treatment for COVID-19...
ARCA biopharma Announces Submission of PCT Patent Application for the Treatment of Coronavirus Infection and Associated Coagulopathy with rNAPc2
09 août 2021 08h00 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., Aug. 09, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...
Pardes Biosciences Appoints Deborah M. Autor, J.D. and Laura J. Hamill to Board of Directors
05 août 2021 07h00 HE
|
Pardes Biosciences, Inc
CARLSBAD, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc., an early-stage biopharmaceutical company developing PBI-0451 as a potential direct-acting, oral antiviral drug to treat...
ARCA biopharma Provides Update on ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19
13 juil. 2021 08h00 HE
|
ARCA biopharma, Inc.
rNAPc2 development focused on unmet need for treatments in hospitalized COVID-19 patientsTrial expanded to South America, with regulatory approvals for Argentina and BrazilTarget trial enrollment...
Adamis Provides Update on Clinical Trial Start-Up Progress for Tempol in the Treatment of COVID-19
11 juin 2021 07h30 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, June 11, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that clinical trial start-up activities are underway for examining the effects of...
Antiviral Drugs Market Value Projected To Reach US$ 74.7 Billion By 2027: Acumen Research And Consulting
01 avr. 2021 11h16 HE
|
Acumen Research and Consulting
Acumen Research and Consulting, a global provider of market research studies, in a recently published report titled “Antiviral Drugs Market– Global Industry Analysis, Market Size, Opportunities and...
Cambridge Security Seals Broadens Offering to Airlines In Anticipation of Global Travel Rebound
02 févr. 2021 10h20 HE
|
Cambridge Security Seals
Pomona, New York, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Cambridge Security Seals (CSS), a global leader and innovator in tamper-evident seals and security solutions, announced today that it had expanded...
ARCA biopharma Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 (AB201) as a Potential Treatment for COVID-19
15 déc. 2020 08h30 HE
|
ARCA biopharma, Inc.
rNAPc2 development focused on unmet need for treatments in hospitalized COVID-19 patients, including after availability of vaccinesrNAPc2 is the only novel compound being developed for COVID-19...